scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Alginate dressings for treating pressure ulcers

TL;DR: The relative effects of alginate dressings compared with alternative treatments are unclear and decision makers may wish to consider aspects such as cost of dressings and the wound management properties offered by each dressing type, for example, exudate management.
Abstract: Background: Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying tissue, or both. Dressings are widely used to treat pressure ulcers and there are many options to choose from including alginate dressings. A clear and current overview of current evidence is required to facilitate decision-making regarding dressing use for the treatment of pressure ulcers. This review is part of a suite of Cochrane reviews investigating the use of dressings in the treatment of pressure ulcers. Each review will focus on a particular dressing type. Objectives: To assess the effects of alginate dressings for treating pressure ulcers in any care setting. Search methods: For this review, in April 2015 we searched the following databases the Cochrane Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid EMBASE; and EBSCO CINAHL. There were no restrictions based on language or date of publication. Selection criteria: Published or unpublished randomised controlled trials (RCTs) comparing the effects of alginate with alternative wound dressings or no dressing in the treatment of pressure ulcers (stage II or above). Data collection and analysis Two review authors independently performed study selection, risk of bias assessment and data extraction. Main results: We included six studies (336 participants) in this review; all studies had two arms. The included studies compared alginate dressings with six other interventions that included: hydrocolloid dressings, silver containing alginate dressings, and radiant heat therapy. Each of the six comparisons included just one study and these had limited participant numbers and short follow-up times. All the evidence was of low or very low quality. Where data were available there was no evidence of a difference between alginate dressings and alternative treatments in terms of complete wound healing or adverse events. Authors' conclusions: The relative effects of alginate dressings compared with alternative treatments are unclear. The existing trials are small, of short duration and at risk of bias. Decision makers may wish to consider aspects such as cost of dressings and the wound management properties offered by each dressing type, for example, exudate management.

Summary (1 min read)

Background

  • Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying tissue, or both.
  • Dressings are widely used to treat pressure ulcers and there are many options to choose from including alginate dressings.
  • A clear and current overview of current evidence is required to facilitate decision-making regarding dressing use for the treatment of pressure ulcers.
  • Each review will focus on a particular dressing type.

Main results

  • The authors included six studies (336 participants) in this review; all studies had two arms.
  • The included studies compared alginate dressings with six other interventions that included: hydrocolloid dressings, silver containing alginate dressings, and radiant heat therapy.
  • Each of the six comparisons included just one study and these had limited participant numbers and short follow-up times.
  • All the evidence was of low or very low quality.
  • 1Alginate dressings for treating pressure ulcers Copyright © 2015 The Cochrane Collaboration.

Authors’ conclusions

  • The relative effects of alginate dressings compared with alternative treatments are unclear.
  • Pressure ulcers can be painful, may become infected, and so affect people’s quality of life.
  • Generally, the studies the authors found did not have many participants and the results were often inconclusive.
  • More research of better quality is needed to find out if alginate dressings are better at healing pressure ulcers than other types of dressings or other treatments.
  • The mean reduction in ulcer size (compared to baseline) was 42.5%.

Did you find this useful? Give us your feedback

Content maybe subject to copyright    Report

Alginate dressings for treating pressure ulcers (Review)
Author
Dumville, Jo C, Keogh, Samantha J, Liu, Zhenmi, Stubbs, Nikki, Walker, Rachel M, Fortnam,
Mathew
Published
2015
Journal Title
Cochrane Database of Systematic Reviews
Version
Version of Record (VoR)
DOI
https://doi.org/10.1002/14651858.CD011277.pub2
Copyright Statement
© 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This review is
published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2015,
Issue 5. Cochrane Reviews are regularly updated as new evidence emerges and in response
to comments and criticisms, and the Cochrane Database of Systematic Reviews should be
consulted for the most recent version of the Review.
Downloaded from
http://hdl.handle.net/10072/81471
Griffith Research Online
https://research-repository.griffith.edu.au

Cochrane Database of Systematic Reviews
Alginate dressings for treating pressure ulcers (Review)
Dumville JC, Keogh SJ, Liu Z, Stubbs N, Walker RM, Fortnam M
Dumville JC, Keogh SJ, Liu Z, Stubbs N, Walker RM, Fortnam M.
Alginate dressings for treating pressure ulcers.
Cochrane Database of Systematic Reviews 2015, Issue 5. Art. No.: CD011277.
DOI: 10.1002/14651858.CD011277.pub2.
www.cochranelibrary.com
Alginate dressings for treating pressure ulcers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
5BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
20ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
28DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29AUTHORS’ CON CLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
46ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
50APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
55CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
55DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
56SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
56DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
56INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iAlginate dressings for treating pressure ulcers (Review)
Copyright © 2015 The Cochrane Colla boration. Published by John Wiley & Sons, Ltd.

[Intervention Review]
Alginate dressings for treating pressure ulcers
Jo C Dumville
1
, Samantha J Keogh
2
, Zhenmi Liu
1
, Nikki Stubbs
3
, Rachel M Walker
2
, Mathew Fortnam
4
1
School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK.
2
NHMRC Centre of Research Excellence
in Nursing, Centre for Health Practice Innovation, Menzies Health Institute Queensland, Griffith University, Brisbane, Australia.
3
Wound Prevention and Management Service, Leeds Community Healthcare NHS Trust, St Mary’s Hospital, Leeds, UK.
4
Cochrane
Wounds Group, University of York, York, UK
Contact address: Jo C Dumville, School of Nursing, Midwifery and Social Work, University of Manchester, Manchester, M13 9PL,
UK.
jo.dumville@manchester. ac.uk.
Editorial group: Cochrane Wounds Group.
Publication s tatus and date: New, published in Issue 5, 2015.
Review content assessed as up-to-date: 14 April 2015.
Citation: Dumville JC, Keogh SJ, Liu Z, Stubbs N, Walker RM, Fortnam M. Alginate dressings for treating pressure ulce r s. Cochrane
Database of Systematic Reviews 2015, Issue 5. Art. No.: CD011277. DOI: 10.1002/14651858.CD011277.pub2.
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying
tissue, or both. Dressings are widely used to treat pressure ulcers and there are many options to choose from including alginate dressings.
A clear and current overview of current evidence is required to facilitate decision-making regarding dressing use for the treatment of
pressure ul cers. This review is part of a suite of Cochrane reviews investigating the use of dressings in the treatment of pressure ulcers.
Each review will focus on a particular dressing type.
Objectives
To assess the effects of alginate dressings for treating pressure ulce r s in any care setting.
Search methods
For this review, in April 2015 we searched the following databases the Cochrane Wounds Group Specialised Register; The Cochrane
Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other
Non-Indexed Citations); Ovid EMBASE; and EBSCO CINAHL. There were no restrictions based on language or date of publication.
Selection criteria
Published or unpublished randomised controlled trials (RCTs) comparing the effects of alginate with alternative wound dressings or
no dressing in the treatment of pressure ulcers (stage II or above).
Data collection and analysis
Two review authors independently performed study selection, risk of bias assessment and data extraction.
Main results
We included six studies (336 participants) in this review; all studies had two arms. The included studies compared alginate dressings
with six other interventions that included: hydrocolloid dressings, silver containing alginate dressings, and radiant heat therapy. Each of
the six comparisons included just one study and these had limited participant numbers and short follow-up times. All the evidence was
of low or very low quality. Where data were available there was no evidence of a diff erence between alginate dressings and alternative
treatments in terms of complete wound healing or adverse events.
1Alginate dressings for treating pressure ulcers (Review)
Copyright © 2015 The Cochrane Colla boration. Published by John Wiley & Sons, Ltd.

Authors conclusions
The relative effects of alginate dressings compared with alternative treatments are unclear. The existing trials are small, of short duration
and at risk of bias. Decision makers may wish to consider aspects such as cost of dressings and the wound management properties
offered by each dressing type, for example, exudate management.
P L A I N L A N G U A G E S U M M A R Y
Alginate dressings for treating pressure ulcers
What are pressure ulcers, and who is at risk?
Pressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are wounds involving the skin and sometimes the
tissue th at lies underneath. Pressure ulcers can be painful, may become infected, and so affect people’s quality of life. People at risk of
developing pressure ulcers include those with spinal cord injuries, and those who are immobile or who have limited mobility - such as
elderly people and people who are ill as a result of short-term or long-term medical conditions.
In 2004 the total annual cost of treating pressure ulcers in the UK was estimated as being GBP 1.4 to 2.1 billion, which was equivalent
to 4% of the total National Health Service expenditure. Pe ople with pressure ulcers have longer stays in hospital, and this increases
hospital costs. Figures from th e USA for 2006 suggest that hal f a million hospital stays had ’pressure ulcer’ noted as a diagnosis; the
total hospital costs of these stays was USD 11 billion.
Why use alginate dressings to treat pressure ulcers?
Dressings are one treatment option for pressure ulcers. There are many types of dressings that can be used; these can vary considerably
in cost. Alginate dressings are a type that is highly absorbant and so can absorb the fluid (exudate) that is produced by some ulcers.
What we found
In June 2014 we searched for as many relevant studies as we could find that had a robust design (randomised controlled trials) and
compared alginate dressings with other treatments for pressure ulcers. We found 6 studies involving a total of 336 participants. Alginates
have been compared with hydrocolloid dressings, another type of alginate dressing, dextranomer paste dressing, silver-alginate dressing,
silver-zinc sulfadiazine cream and treatment with a radiant heat system in these studies. There was no evidence from these studies to
suggest that alginate wound dressings are more effective at healing pressure ulcers than other types of dressings or skin surface (topical)
treatments, or other interventions.
Generally, the studies we found did not have many participants and the results were often inconclusive. Some study reports did not
provide information about how they were conducted and it was difficult to tel l whether the results presented were likely to be true.
More research of better quality is needed to find out if alginate dressings are better at healing pressure ulcers than other types of dressings
or other treatments. This review is part of a suite of reviews investigating dressings for the treatment of pressure ulcers
This plain language summary is up-to-date as of June 2014.
2Alginate dressings for treating pressure ulcers (Review)
Copyright © 2015 The Cochrane Colla boration. Published by John Wiley & Sons, Ltd.

Citations
More filters
Journal ArticleDOI
TL;DR: The effects of most interventions for preventing and treating pressure ulcers in people with spinal cord injury are highly uncertain and there is still a need for high-quality randomised trials of such interventions in this patient population.
Abstract: Narrative review. Pressure ulcers are a common complication in people with reduced sensation and limited mobility, occurring frequently in those who have sustained spinal cord injury. This narrative review summarises the evidence relating to interventions for the prevention and treatment of pressure ulcers, in particular from Cochrane systematic reviews. It also aims to highlight the degree to which people with spinal cord injury have been included as participants in randomised controlled trials included in Cochrane reviews of such interventions. Global. The Cochrane library (up to July 2017) was searched for systematic reviews of any type of intervention for the prevention or treatment of pressure ulcers. A search of PubMed (up to July 2017) was undertaken to identify other systematic reviews and additional published trial reports of interventions for pressure ulcer prevention and treatment. The searches revealed 38 published systematic reviews (27 Cochrane and 11 others) and 6 additional published trial reports. An array of interventions is available for clinical use, but few have been evaluated adequately in people with SCI. The effects of most interventions for preventing and treating pressure ulcers in people with spinal cord injury are highly uncertain. Existing evaluations of pressure ulcer interventions include very few participants with spinal cord injury. Subsequently, there is still a need for high-quality randomised trials of such interventions in this patient population.

35 citations

Journal ArticleDOI
TL;DR: An extensive overview of recent research regarding promising cellulose derivatives-based materials for the development of multiple biomedical and pharmaceutical applications, such as wound dressings, drug delivery devices, and tissue engineering can be found in this paper.
Abstract: Presently, notwithstanding the progress regarding wound-healing management, the treatment of the majority of skin lesions still represents a serious challenge for biomedical and pharmaceutical industries. Thus, the attention of the researchers has turned to the development of novel materials based on cellulose derivatives. Cellulose derivatives are semi-synthetic biopolymers, which exhibit high solubility in water and represent an advantageous alternative to water-insoluble cellulose. These biopolymers possess excellent properties, such as biocompatibility, biodegradability, sustainability, non-toxicity, non-immunogenicity, thermo-gelling behavior, mechanical strength, abundance, low costs, antibacterial effect, and high hydrophilicity. They have an efficient ability to absorb and retain a large quantity of wound exudates in the interstitial sites of their networks and can maintain optimal local moisture. Cellulose derivatives also represent a proper scaffold to incorporate various bioactive agents with beneficial therapeutic effects on skin tissue restoration. Due to these suitable and versatile characteristics, cellulose derivatives are attractive and captivating materials for wound-healing applications. This review presents an extensive overview of recent research regarding promising cellulose derivatives-based materials for the development of multiple biomedical and pharmaceutical applications, such as wound dressings, drug delivery devices, and tissue engineering.

27 citations

Journal ArticleDOI
TL;DR: In this paper , the authors present the subjectively selected nanomaterials used in wound dressings, including the metallic nanoparticles (NPs), and refer to the aspects of their application as antimicrobial factors.
Abstract: Wound management is the burning problem of modern medicine, significantly burdening developed countries’ healthcare systems. In recent years, it has become clear that the achievements of nanotechnology have introduced a new quality in wound healing. The application of nanomaterials in wound dressing significantly improves their properties and promotes the healing of injuries. Therefore, this review paper presents the subjectively selected nanomaterials used in wound dressings, including the metallic nanoparticles (NPs), and refers to the aspects of their application as antimicrobial factors. The literature review was supplemented with the results of our team’s research on the elements of multifunctional new-generation dressings containing nanoparticles. The wound healing multiple molecular pathways, mediating cell types, and affecting agents are discussed herein. Moreover, the categorization of wound dressings is presented. Additionally, some materials and membrane constructs applied in wound dressings are described. Finally, bacterial participation in wound healing and the mechanism of the antibacterial function of nanoparticles are considered. Membranes involving NPs as the bacteriostatic factors for improving wound healing of skin and bones, including our experimental findings, are discussed in the paper. In addition, some studies of our team concerning the selected bacterial strains’ interaction with material involving different metallic NPs, such as AuNPs, AgNPs, Fe3O4NPs, and CuNPs, are presented. Furthermore, nanoparticles’ influence on selected eukaryotic cells is mentioned. The ideal, universal wound dressing still has not been obtained; thus, a new generation of products have been developed, represented by the nanocomposite materials with antibacterial, anti-inflammatory properties that can influence the wound-healing process.

13 citations

Journal ArticleDOI
TL;DR: This meta-synthesis confirms the low-certainty of PI prevention and treatment trials, resulting in few recommendations to inform clinical practice.

12 citations

Journal ArticleDOI
TL;DR: This investigation was the first known attempt to conduct a multicenter analysis of wound epidemiology in Portugal, which included all care settings, and identified a higher frequency and prevalence of severe ulcers in hospital and nursing home populations.

10 citations

References
More filters
Journal ArticleDOI
04 Sep 2003-BMJ
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Abstract: Cochrane Reviews have recently started including the quantity I 2 to help readers assess the consistency of the results of studies in meta-analyses. What does this new quantity mean, and why is assessment of heterogeneity so important to clinical practice? Systematic reviews and meta-analyses can provide convincing and reliable evidence relevant to many aspects of medicine and health care.1 Their value is especially clear when the results of the studies they include show clinically important effects of similar magnitude. However, the conclusions are less clear when the included studies have differing results. In an attempt to establish whether studies are consistent, reports of meta-analyses commonly present a statistical test of heterogeneity. The test seeks to determine whether there are genuine differences underlying the results of the studies (heterogeneity), or whether the variation in findings is compatible with chance alone (homogeneity). However, the test is susceptible to the number of trials included in the meta-analysis. We have developed a new quantity, I 2, which we believe gives a better measure of the consistency between trials in a meta-analysis. Assessment of the consistency of effects across studies is an essential part of meta-analysis. Unless we know how consistent the results of studies are, we cannot determine the generalisability of the findings of the meta-analysis. Indeed, several hierarchical systems for grading evidence state that the results of studies must be consistent or homogeneous to obtain the highest grading.2–4 Tests for heterogeneity are commonly used to decide on methods for combining studies and for concluding consistency or inconsistency of findings.5 6 But what does the test achieve in practice, and how should the resulting P values be interpreted? A test for heterogeneity examines the null hypothesis that all studies are evaluating the same effect. The usual test statistic …

45,105 citations

Journal ArticleDOI
TL;DR: An Explanation and Elaboration of the PRISMA Statement is presented and updated guidelines for the reporting of systematic reviews and meta-analyses are presented.
Abstract: Systematic reviews and meta-analyses are essential to summarize evidence relating to efficacy and safety of health care interventions accurately and reliably. The clarity and transparency of these reports, however, is not optimal. Poor reporting of systematic reviews diminishes their value to clinicians, policy makers, and other users. Since the development of the QUOROM (QUality Of Reporting Of Meta-analysis) Statement—a reporting guideline published in 1999—there have been several conceptual, methodological, and practical advances regarding the conduct and reporting of systematic reviews and meta-analyses. Also, reviews of published systematic reviews have found that key information about these studies is often poorly reported. Realizing these issues, an international group that included experienced authors and methodologists developed PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) as an evolution of the original QUOROM guideline for systematic reviews and meta-analyses of evaluations of health care interventions. The PRISMA Statement consists of a 27-item checklist and a four-phase flow diagram. The checklist includes items deemed essential for transparent reporting of a systematic review. In this Explanation and Elaboration document, we explain the meaning and rationale for each checklist item. For each item, we include an example of good reporting and, where possible, references to relevant empirical studies and methodological literature. The PRISMA Statement, this document, and the associated Web site (http://www.prisma-statement.org/) should be helpful resources to improve reporting of systematic reviews and meta-analyses.

25,711 citations

Journal ArticleDOI
24 Mar 2010-BMJ
TL;DR: The Consort 2010 Statement as discussed by the authors has been used worldwide to improve the reporting of randomised controlled trials and has been updated by Schulz et al. in 2010, based on new methodological evidence and accumulating experience.
Abstract: The CONSORT statement is used worldwide to improve the reporting of randomised controlled trials. Kenneth Schulz and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on new methodological evidence and accumulating experience. To encourage dissemination of the CONSORT 2010 Statement, this article is freely accessible on bmj.com and will also be published in the Lancet, Obstetrics and Gynecology, PLoS Medicine, Annals of Internal Medicine, Open Medicine, Journal of Clinical Epidemiology, BMC Medicine, and Trials.

11,165 citations

Journal ArticleDOI
TL;DR: The 2010 version of the CONSORT Statement is described, which updates the previous reporting guideline based on new methodological evidence and accumulated experience.
Abstract: Kenneth Schulz and colleagues describe the 2010 version of the CONSORT Statement, which updates the previous reporting guideline based on new methodological evidence and accumulated experience.

5,090 citations

Journal ArticleDOI
07 Jun 2007-Trials
TL;DR: This practical guide should improve the quality of the analysis and subsequent interpretation of systematic reviews and meta-analyses that include time-to-event outcomes and provide a corresponding, easy- to-use calculations spreadsheet, to facilitate the computational aspects.
Abstract: In systematic reviews and meta-analyses, time-to-event outcomes are most appropriately analysed using hazard ratios (HRs). In the absence of individual patient data (IPD), methods are available to obtain HRs and/or associated statistics by carefully manipulating published or other summary data. Awareness and adoption of these methods is somewhat limited, perhaps because they are published in the statistical literature using statistical notation. This paper aims to 'translate' the methods for estimating a HR and associated statistics from published time-to-event-analyses into less statistical and more practical guidance and provide a corresponding, easy-to-use calculations spreadsheet, to facilitate the computational aspects. A wider audience should be able to understand published time-to-event data in individual trial reports and use it more appropriately in meta-analysis. When faced with particular circumstances, readers can refer to the relevant sections of the paper. The spreadsheet can be used to assist them in carrying out the calculations. The methods cannot circumvent the potential biases associated with relying on published data for systematic reviews and meta-analysis. However, this practical guide should improve the quality of the analysis and subsequent interpretation of systematic reviews and meta-analyses that include time-to-event outcomes.

4,641 citations

Frequently Asked Questions (6)
Q1. What are the types of people at risk of developing pressure ulcers?

People at risk of developing pressure ulcers include those with spinal cord injuries, and those who are immobile or who have limited mobility - such as elderly people and people who are ill as a result of short-term or long-term medical conditions. 

In 2004 the total annual cost of treating pressure ulcers in the UK was estimated as being GBP 1.4 to 2.1 billion, which was equivalent to 4% of the total National Health Service expenditure. 

Published by John Wiley & Sons, Ltd.A B S T R A C TPressure ulcers, also known as bedsores, decubitus ulcers and pressure injuries, are localised areas of injury to the skin or the underlying tissue, or both. 

Figures from the USA for 2006 suggest that half a million hospital stays had ’pressure ulcer’ noted as a diagnosis; the total hospital costs of these stays was USD 11 billion. 

For this review, in April 2015 the authors searched the following databases the Cochrane Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid EMBASE; and EBSCO CINAHL. 

GRADE Working Group grades of evidence High quality: further research is very unlikely to change their confidence in the estimate of effect Moderate quality: further research is likely to have an important impact on their confidence in the estimate of effect and may change the estimate Low quality: further research is very likely to have an important impact on their confidence in the estimate of effect and is likely to change the estimate Very low quality: the authors are very uncertain about the estimate1